Radka Obermannová

Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Florian Lordick, C. Mariette, Karin Haustermans et al. · Annals of Oncology · 2016 · 1.1K citations · Full text

Medicine, Oncology, Surgery +14

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn et al. · The Lancet Oncology · 2015 · 955 citations

Medicine, Oncology, Pharmacotherapy +12

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Radka Obermannová, María Alsina, Andrés Cervantes et al. · Annals of Oncology · 2022 · 656 citations · Full text

Medicine, Oncology, Surgery +14

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study

Bohuslav Melichar, Antoine Adenis, A. Craig Lockhart et al. · The Lancet Oncology · 2015 · 251 citations

Medicine, Oncology, Pharmacology +15